Testagen
Aliases: Lys-Glu-Asp · KED peptide
Last verified: 2026-09-24
The short version
Testagen is the 'hormonal' bioregulator — the most attractive possible marketing inside the weakest possible category. The promise is clear: 'natural testosterone support'. But a three-amino-acid peptide taken orally passes through the gastrointestinal cascade of aminopeptidases, and the 'testicular factor' story never received independent confirmation. Besides: whatever effect might exist would be subtle — unlike real interventions (training, sleep, treating hypogonadism) which have large and measurable effects. This is a substance that sells desire, not results.
Identity & type
- Molecular type
- bioregulator peptide
- Sequence / structure
- Lys-Glu-Asp (3 aa)
- Molecular weight
- ~404 Da
- Origin
- A synthetic tripeptide from the Soviet-Russian program; the name suggests a testicular bioregulator.
Mechanism of action
A tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator program; claimed to modulate testicular function and sex-hormone secretion via 'peptide factor' signaling — publications come from the same source as all bioregulators.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Rare; among users who cyclically take several bioregulators at once, without hormone measurements before/after.
Unverified self-reports. Not medical advice. Not endorsement.
Protocol — official vs community
Official / label
No approved protocol exists. Testagen is a research peptide bioregulator (Lys-Glu-Asp) with no registered drug product in any major market.
Duration: —
Testicular-function and sex-hormone claims come from the same single-source publication family as the rest of the series; no standardized trial data.
Community (anecdotal)
5–10 mg SC daily for 10–15 days, or 1–2 mg orally per the program pattern.
- Cycle:
- 1–2 courses per year.
- Break:
- Months between courses.
Follows the program-pattern variant of the shared course structure; only the testis/testosterone targeting claim distinguishes it from the rest of the series.
Human evidence
None — controlled human trials have not been conducted.
Preclinical evidence
Limited, single-source: old models with statistically modest samples.
Known risks
- Delaying real endocrine treatment for hypogonadism symptomstheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Everything — no independent human data
Frequently asked questions
References
- Khavinson group publications on testicular peptide bioregulators (single-source literature)